DDInter927 DDInter1248
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent. Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with
Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease.
Mumps virus strain B level jeryl lynn live antigen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tetracosactide
Mumps virus strain B level jeryl lynn live antigen {u} may lead to a major life threatening interaction when taken with {v} Bosutinib
Mumps virus strain B level jeryl lynn live antigen {u} may lead to a major life threatening interaction when taken with {v} Durvalumab
Mumps virus strain B level jeryl lynn live antigen may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Bosutinib
Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Durvalumab